EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy

Aaron W Michels, Peter A Gottlieb, Bryce Nelson, Colin Dayan

Diabetes/Metabolism Research and Reviews · 2025-10 · 41 (7)

DOI: 10.1002/dmrr.70091 ↗

At a glance

Übersichtsarbeit in Diabetes/Metabolism Research and Reviews, published online on 2025-10-09. Written by Aaron W Michels and 3 co-authors. Institution: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Major MEDLINE topics: Diabetes Mellitus, Type 1, Immunotherapy. Cited 6 times so far (Crossref); 151 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, Sanofi.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Disease‐modifying therapies have been used to treat the underlying causes of autoimmune diseases for over half a century. However, until recently, type 1 diabetes (T1D), the autoimmune form of diabetes, had not entered this therapeutic landscape. The approval of teplizumab, an anti‐CD3 monoclonal antibody and the first disease‐modifying therapy for use in individuals with preclinical T1D, has caused a major shift in the way healthcare providers can treat the T1D disease course. In this review, we discuss the chronic autoimmune nature of T1D and provide an overview of disease‐modifying therapies that are under investigation to target the autoimmune mechanisms in T1D to preserve residual beta‐cell function and prevent disease progression. The considerations for implementing these therapies into clinical practice are also discussed.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1ImmunotherapyHumansAntibodies, Monoclonal, Humanized

Author keywords

autoimmunedisease‐modifying therapyprogressionscreeningteplizumabtype 1 diabetes

Substances

Antibodies, Monoclonal, Humanizedteplizumab

Authors and institutions

  • Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Cardiff University, Cardiff, UK.

Funding

  • NIDDK NIH HHS
  • Sanofi

Cite

APA

Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. (2025). Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews, 41(7). https://doi.org/10.1002/dmrr.70091

Vancouver

Michels AW, Gottlieb PA, Nelson B, Dayan C. Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews. 2025;41(7). doi:10.1002/dmrr.70091

BibTeX
@article{Michels2025,
  author = {Michels, Aaron W and Gottlieb, Peter A and Nelson, Bryce and Dayan, Colin},
  title = {Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  volume = {41},
  number = {7},
  doi = {10.1002/dmrr.70091}
}
Start for free →